Mr. Andre Godin of Neptune reports

NEPTUNE AND BLUEOCEAN SIGN LICENSING AGREEMENT

Neptune Technologies & Bioressources Inc. has signed an exclusive worldwide, royalty-bearing, non-transferable licence agreement with Blueocean Nutrascience Inc. under Neptune's composition and extraction patents covering the production and sale of marine-derived oil products containing phospholipids. The licence allows Blueocean and its shrimp joint venture affiliate to produce and sell shrimp oil products extracted from three species of North Atlantic cold-water shrimp (Pandalus borealis, Pandalus montagui and Pandalus jordani) in the nutraceutical, dietary ingredients, natural health products, functional food and food supplements markets. The medical food, drugs and drug product markets are not included.

The commercial terms of the licence include Blueocean paying Neptune a minimum yearly cash royalty, and a royalty per unit of product sold. As well, an initial upfront payment will be payable at closing through the issuance of Blueocean shares. Closing of the transaction is being done at arm's length and is subject to approval of the TSX Venture Exchange. No finder's fee is being paid in connection with this transaction.

"Neptune's intellectual property is an integral part of shareholder value creation and today's announcement further acknowledges Neptune's pioneering role and patent recognition by industry partners," commented Andre Godin, interim president and chief executive officer of Neptune. "Neptune's patents cover oils and phospholipids extracted from marine and aquatic biomass, including shrimp and the licence further endorses the strength, value and validity of Neptune's IP."

We seek Safe Harbor.